

## Volume 2

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

### **1 Angiosarcoma — 1**

- 1.1 Uterine angiosarcoma — **1**
- 1.1.1 General, epidemiology, etiology, pathogenesis, staging — **1**
- 1.1.2 Macroscopic and microscopic features — **2**
- 1.1.3 Clinical presentation, diagnostics, screening — **4**
- 1.1.4 Imaging — **4**
- 1.1.5 Differential diagnostics — **5**
- 1.1.6 Course, prognosis — **6**
- 1.1.7 Primary surgery — **6**
- 1.1.8 Adjuvant and additive radio-, chemo- and hormone therapy — **8**
- 1.1.9 Primary radio-, chemo- and hormone therapy, approach in cases of general inoperability — **9**
- 1.1.10 Aftercare, recurrences, metastases — **10**
- 1.1.11 Surgery and postoperative additive therapy for recurrences and metastases — **10**
- 1.1.12 Palliative radio-, chemo- and hormone therapy, small molecule therapy, supportive therapy — **12**
- 1.2 Extrauterine angiosarcomas — **14**
- 1.2.1 Angiosarcomas of the vulva and the vagina — **14**
- 1.2.2 Angiosarcoma of the ovary and the tuba uterina — **18**

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

### **2 Liposarcoma — 29**

- 2.1 Uterine liposarcoma — **29**

|        |                                                                                                    |           |
|--------|----------------------------------------------------------------------------------------------------|-----------|
| 2.1.1  | General, epidemiology, etiology, pathogenesis, staging —                                           | <b>29</b> |
| 2.1.2  | Macroscopic and microscopic features —                                                             | <b>31</b> |
| 2.1.3  | Clinical presentation, diagnostics, screening —                                                    | <b>35</b> |
| 2.1.4  | Imaging —                                                                                          | <b>35</b> |
| 2.1.5  | Differential diagnostics —                                                                         | <b>40</b> |
| 2.1.6  | Course, prognosis —                                                                                | <b>40</b> |
| 2.1.7  | Primary surgery —                                                                                  | <b>42</b> |
| 2.1.8  | Adjuvant and additive radio-, chemo- and hormone therapy —                                         | <b>43</b> |
| 2.1.9  | Primary radio-, chemo- and hormone therapy, approach in cases of general inoperability —           | <b>45</b> |
| 2.1.10 | Aftercare, recurrences, metastases —                                                               | <b>46</b> |
| 2.1.11 | Surgical management of and postoperative additive therapy for recurrences and metastatic disease — | <b>48</b> |
| 2.1.12 | Palliative radio-, chemo- and hormone therapy, therapy with small molecules, supportive therapy —  | <b>49</b> |
| 2.2    | Extrauterine liposarcomas —                                                                        | <b>51</b> |
| 2.2.1  | Liposarcoma of the vulva and the vagina —                                                          | <b>51</b> |
| 2.2.2  | Peritoneal liposarcoma —                                                                           | <b>56</b> |

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

|          |                                                                                                 |            |
|----------|-------------------------------------------------------------------------------------------------|------------|
| <b>3</b> | <b>Rhabdomyosarcoma —</b>                                                                       | <b>63</b>  |
| 3.1      | Uterine rhabdomyosarcoma —                                                                      | <b>64</b>  |
| 3.1.1    | General, epidemiology, etiology, pathogenesis, staging —                                        | <b>64</b>  |
| 3.1.2    | Macroscopic and microscopic features —                                                          | <b>70</b>  |
| 3.1.3    | Clinical presentation, diagnostics, screening —                                                 | <b>73</b>  |
| 3.1.4    | Imaging —                                                                                       | <b>75</b>  |
| 3.1.5    | Differential diagnostics —                                                                      | <b>77</b>  |
| 3.1.6    | Course, prognosis —                                                                             | <b>78</b>  |
| 3.1.7    | Primary surgery —                                                                               | <b>83</b>  |
| 3.1.8    | Adjuvant and additive radio-, chemo- and hormone therapy —                                      | <b>87</b>  |
| 3.1.9    | Primary radiation, hormone and chemotherapy, approach in cases of general inoperability —       | <b>91</b>  |
| 3.1.10   | Aftercare, recurrences, metastases —                                                            | <b>94</b>  |
| 3.1.11   | Surgical management and postoperative additive therapy for recurrences and metastatic disease — | <b>95</b>  |
| 3.1.12   | Palliative radiotherapy, chemotherapy and hormone therapy, therapy with small molecules —       | <b>96</b>  |
| 3.2      | Extrauterine rhabdomyosarcoma —                                                                 | <b>98</b>  |
| 3.2.1    | Rhabdomyosarcoma of the ovary and the fallopian tube —                                          | <b>98</b>  |
| 3.2.2    | Rhabdomyosarcomas of the vulva and the vagina —                                                 | <b>102</b> |

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

#### **4 Perivascular epithelioid cell tumor (PEComa) — 117**

- 4.1 PEComa of the uterus — **117**
  - 4.1.1 General, epidemiology, etiology, pathogenesis, staging — **117**
  - 4.1.2 Macroscopic and microscopic features — **119**
  - 4.1.3 Clinical presentation, diagnostics, screening — **122**
  - 4.1.4 Imaging — **123**
  - 4.1.5 Differential diagnostics — **125**
  - 4.1.6 Course, prognosis — **128**
  - 4.1.7 Primary surgery — **128**
  - 4.1.8 Adjuvant and additive radio-, chemo- and hormone therapy — **129**
  - 4.1.9 Primary radio-, chemo- and hormone therapy, approach in cases of general inoperability — **130**
  - 4.1.10 Aftercare, recurrences, metastases — **131**
  - 4.1.11 Surgical management and postoperative additive treatment for recurrences and metastatic disease — **132**
  - 4.1.12 Palliative radio-, chemo- and hormone therapy, therapy with small molecules, supportive therapy — **133**
- 4.2 Extrauterine and extragenital PEComas — **135**
  - 4.2.1 General, pathogenesis, pathologic-anatomical features — **135**
  - 4.2.2 Clinical presentation, diagnostics, imaging, differential diagnostics — **136**
  - 4.2.3 Course, prognosis, operative, systemic and radiogenic therapy — **138**

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

#### **5 Adenofibroma — 143**

- 5.1 Uterine adenofibroma — **143**
  - 5.1.1 General, pathogenesis, pathologico-anatomical features — **143**
  - 5.1.2 Clinical presentation, diagnostics, imaging, differential diagnostics, screening — **146**
  - 5.1.3 Course, prognosis, operative, systemic and radiogenic therapy — **148**
  - 5.1.4 Aftercare, recurrences, metastases and their treatment — **150**
- 5.2 Extrauterine adenofibromas — **151**
  - 5.2.1 Adenofibromas of the ovary and the fallopian tube — **151**

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

#### **6 Adenosarcoma — 157**

- 6.1 Uterine adenosarcoma — **157**
  - 6.1.1 General, epidemiology, etiology, pathogenesis, staging — **157**
  - 6.1.2 Macroscopic and microscopic features — **159**
  - 6.1.3 Clinical presentation, diagnostics, screening — **165**
  - 6.1.4 Imaging — **166**

- 6.1.5 Differential diagnostics — **171**
- 6.1.6 Course, prognosis — **173**
- 6.1.7 Primary surgery — **176**
- 6.1.8 Adjuvant and additive radio-, chemo- and hormone therapy — **180**
- 6.1.9 Primary radio-, chemo- and hormone therapy, approach in cases of general inoperability — **184**
- 6.1.10 Aftercare, recurrences, metastases — **186**
- 6.1.11 Surgical management and postoperative additive therapy for recurrences and metastatic disease — **188**
- 6.1.12 Palliative radio-, chemo- and hormone therapy, treatment with small molecules, supportive therapy — **190**
- 6.2 Extrauterine and extragenital adenosarcomas — **194**
- 6.2.1 Adenosarcomas of the ovary and the fallopian tube — **194**
- 6.2.2 Adenosarcoma of the vagina — **196**
- 6.2.3 Extragenital adenosarcomas — **196**

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

**7 Carcinosarcoma — 205**

- 7.1 Uterine carcinosarcoma — **205**
- 7.1.1 General, epidemiology, etiology, pathogenesis, staging — **205**
- 7.1.2 Macroscopic and microscopic features — **209**
- 7.1.3 Clinical presentation, diagnostics, screening — **217**
- 7.1.4 Imaging — **219**
- 7.1.5 Differential diagnostics — **226**
- 7.1.6 Course, prognosis — **230**
- 7.1.7 Primary surgery — **234**
- 7.1.8 Adjuvant and additive radio-, chemo- and hormone therapy — **239**
- 7.1.9 Primary radio-, chemo- and hormone therapy, approach in case of general inoperability — **248**
- 7.1.10 Aftercare, recurrences, metastases — **250**
- 7.1.11 Surgical and postoperative additive treatment for recurrences and metastatic disease — **252**
- 7.1.12 Palliative radio-, chemo- and hormone therapy, therapy with small molecules, supportive therapy — **254**
- 7.2 Extrauterine carcinosarcoma — **261**
- 7.2.1 Carcinosarcoma of the ovary — **261**
- 7.2.2 Carcinosarcoma of the fallopian tube — **276**
- 7.2.3 Peritoneal carcinosarcoma — **277**
- 7.2.4 Extraperitoneal carcinosarcoma — **278**

Marek Zygmunt, Matthias Evert, Katja Evert and Günter Köhler

- 8 Fertility and pregnancy and variants of leiomyoma, smooth muscle tumors of unclear malignant potential, stromal tumors, genital sarcomas, PEComas and mixed tumors — 297**
- 8.1 General, symptoms, clinical presentation, diagnostics, differential diagnostics, prognosis — **297**
- 8.2 Disseminated (diffuse) peritoneal leiomyomatosis — **300**
- 8.3 Intravenous (intravascular) leiomyomatosis — **301**
- 8.4 Benign metastasizing leiomyomas — **302**
- 8.5 Leiomyoma and its variants — **303**
- 8.6 Smooth muscle tumors of uncertain malignant potential — **304**
- 8.7 Leiomyosarcoma — **306**
- 8.8 Endometrial stromal nodules and uterine tumors with sex cord-like elements type I and II (ESTSCLE and UTROSCT) — **308**
- 8.9 Low-grade endometrial stromal sarcoma — **309**
- 8.10 High-grade endometrial stromal sarcomas and undifferentiated uterine sarcomas — **312**
- 8.11 Angiosarcoma — **313**
- 8.12 Liposarcoma — **313**
- 8.13 Rhabdomyosarcoma — **315**
- 8.14 PEComa — **316**
- 8.15 Adenofibroma — **316**
- 8.16 Adenosarcoma — **317**
- 8.17 Carcinosarcoma — **317**

**Index — 325**